Article Details

New data show Roche's Itovebi significantly extended survival in - GuruFocus

Retrieved on: 2025-05-31 12:25:33

Tags for this article:

Click the tags to see associated articles and topics

New data show Roche's Itovebi significantly extended survival in - GuruFocus. View article details on hiswai:

Excerpt

Roche's Itovebi (inavolisib) showed a 30% reduction in death risk for PIK3CA-mutated HR-positive advanced breast cancer patients.

Article found on: www.gurufocus.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo